Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases

作者：Bacioglu, Mehtap; Maia, Luis F.; Preische, Oliver; Schelle, Juliane; Apel, Anja; Kaeser, Stephan A.; Schweighauser, Manuel; Eninger, Timo; Lambert, Marius; Pilotto, Andrea; Shimshek, Derya R.; Neumann, Ulf; Kahle, Philipp J.; Staufenbiel, Matthias; Neumann, Manuela; Maetzler, Walter; Kuhle, Jens^*; Jucker, Mathias^*

来源：Neuron, 2016, 91(1): 56-66.

DOI：10.1016/j.neuron.2016.05.018

• SUBUNIT PNF-H
• TRANSGENIC MICE
• CEREBROSPINAL-FLUID
• ALPHA-SYNUCLEIN
• ALZHEIMERS-DISEASE
• NEUROFIBRILLARY TANGLES
• PROGNOSTIC BIOMARKER
• PARKINSONS-DISEASE
• NERVOUS-SYSTEM
• AXONOPATHY

A majority of current disease-modifying therapeutic approaches for age-related neurodegenerative diseases target their characteristic proteopathic lesions (alpha-synuclein, Tau, A beta). To monitor such treatments, fluid biomarkers reflecting the underlying disease process are crucial. We found robust increases of neurofilament light chain (NfL) in CSF and blood in murine models of alpha-synucleinopathies, tauopathy, and beta-amyloidosis. Blood and CSF NfL levels were strongly correlated, and NfL increases coincided with the onset and progression of the corresponding proteopathic lesions in brain. Experimental induction of alpha-synuclein lesions increased CSF and blood NfL levels, while blocking Ab lesions attenuated the NfL increase. Consistently, we also found NfL increases in CSF and blood of human alpha-synucleinopathies, tauopathies, and Alzheimer's disease. Our results suggest that CSF and particularly blood NfL can serve as a reliable and easily accessible biomarker to monitor disease progression and treatment response in mouse models and potentially in human proteopathic neurodegenerative diseases.

• 出版日期2016-7-6